1-3 of 3
Mary Steigelman, RN
Close
Sort by
Journal Articles

The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Wael A. Harb, MD, Nehal Lakhani, MD PhD, Ana Logsdon, LPN, Clinical Research Coordinator, Mary Steigelman, RN, Heidi Smith-Green, BSN, RN, Shari Gaylor, RN, Wendi Rodrigueza, PhD, Michael Woolliscroft, BA, MBA, Mina Sooch, BS, MBA, Richard A. Messmann, MD MHS, MSc, Ayad Al-Katib, MD FACP
Journal: Blood
Blood (2014) 124 (21): 1716.
https://doi.org/10.1182/blood.V124.21.1716.1716
Published: 2014
Journal Articles

The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin’s Lymphoma

Wael A. Harb, MD, Nehal Lakhani, MD, PhD, Ana Logsdon, LPN, Clinical Research Coordinator, Mary Steigelman, RN, Heidi Smith-Green, BSN, RN, Shari Gaylor, RN, Michael Woolliscroft, BA, MBA, Wendi Rodrigueza, Ph.D., Mina Sooch, BS, MBA, Richard A. Messmann, MD, MHS, MSc, Ayad Al-Katib, MD, FACP
Journal: Blood
Blood (2013) 122 (21): 88.
https://doi.org/10.1182/blood.V122.21.88.88
Published: 2013
Journal Articles

Anti CD-20 Radioimmunotherapy (RIT) Can Be Safely and Effectively Delivered in a Community-Based Hospital

Ayad Al-Katib, MD, FACP, Mary Mandziara, NP, Susan Szpunar, PhD, Kleanthe Kolizeras, BS, Mary Steigelman, RN, John Kalabat, MD, Zyad Kafri, MD
Journal: Blood
Blood (2011) 118 (21): 4991.
https://doi.org/10.1182/blood.V118.21.4991.4991
Published: 2011